Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
106.93
(
0.00%
)
Bitcoin
70,344.04
(
-0.24%
)
News Focus
News Focus
Post# of 257268
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 171571

Thursday, 12/19/2013 4:03:04 PM

Thursday, December 19, 2013 4:03:04 PM

Post# of 257268

…unless the PEARL data surprise to the upside…

I presume you’re talking about PEARL-3/4 (treatment-naïve GT1b,GT1a) rather than PEARL-2 (treatment-experienced GT1b) since these are the next trials to report and it would be helpful if ABBV/ENTA can dispense with ribavirin in some or all TN patients.

However, PEARL-2 is a wildcard that offers the possibility of an outcome wholly unexpected by anyone on Wall Street: a patient subgroup (TE GT1b) where GILD’s regimen apparently requires ribavirin and ABBV/ENTA’s doesn’t.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today